<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=29917"><dc:title>The efficacy of cysteamine as a melasma therapy</dc:title><dc:creator>Kusumawardani,	Arie	(Avtor)
	</dc:creator><dc:creator>Octarica,	Stella Gracia	(Avtor)
	</dc:creator><dc:creator>Kusuma Dewi,	Ayu	(Avtor)
	</dc:creator><dc:creator>Sambodo,	Shelly Lavenia	(Avtor)
	</dc:creator><dc:creator>Dwi Utama,	Rahmat Firdaus	(Avtor)
	</dc:creator><dc:creator>Primas Adjie,	Sugih	(Avtor)
	</dc:creator><dc:subject>cysteamine</dc:subject><dc:subject>hyperpigmentation</dc:subject><dc:subject>MASI</dc:subject><dc:subject>melasma</dc:subject><dc:description>Melasma is a chronic and refractory hyperpigmentation disorder that predominantly affects women and individuals with darker skin tones. Treatment remains challenging due to issues related to efficacy, side effects, and high recurrence rates. Cysteamine is a depigmenting agent that has demonstrated promising outcomes in melasma management with minimal adverse effects. This study evaluates the effectiveness of cysteamine as a treatment for melasma. A systematic review was conducted using databases from PubMed, Google Scholar, and ScienceDirect, including articles published over the past 10 years (2013–2023). Eight studies met the inclusion criteria for this review. Cysteamine showed good therapeutic efficacy, reflected in reductions in the melasma area and severity index (MASI) ranging from 1.5 to 10.07, with a mean decrease of 5.73. No severe adverse effects were reported, and only mild reactions such as erythema, itching, irritation, dry skin, tingling, and burning sensations were noted. Overall, cysteamine is demonstrated to be an effective and safe therapy for melasma, offering satisfactory clinical improvement with minimal side effects.</dc:description><dc:publisher>Združenje slovenskih dermatovenerologov</dc:publisher><dc:date>2025</dc:date><dc:date>2026-06-09 08:38:26</dc:date><dc:type>Neznano</dc:type><dc:identifier>29917</dc:identifier><dc:language>sl</dc:language><dc:rights>Na spletni strani revije navedeno: Acta Dermatovenerologica Alpina, Pannonica et Adriatica (ISSN 1318-4458) is an open access medical journal published quarterly by the Association of Slovenian Dermatovenerologists (https://acta-apa.mf.uni-lj.si/index.php); Authors publishing in our journal retain copyright of their work under the Creative Commons Attribution License (CC BY 4.0). This license allows unrestricted use, distribution, and reproduction of the work in any medium, provided the original author(s) and copyright holder(s) are appropriately credited, and the original publication in the journal is properly cited, following established academic practices (https://acta-apa.mf.uni-lj.si/submissions.php).</dc:rights></rdf:Description></rdf:RDF>
